MedTrace Logo

The Effects of Visible Light on the Skin After Administration of Oral Polypodium Leucotomos

NCT02904798 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2022-03-03

No results posted yet for this study

Summary

Polypodium Leucotomos Extract (PLE) is a tropical fern that has antioxidative, photoprotective, chemoprotective, anti-inflammatory, and immunomodulatory properties. The antioxidative effects of PL include inhibition and scavenging of free radicals, lipid peroxidation and reactive oxygen species (ROS) such hydrogen peroxide, superoxide anion, hydroxyl radical and singlet oxygen. Visible light (400-700 nm) causes pigmentation in melanocompetent individuals and induces DNA damage in the human skin through ROS production. The goal of this study is to determine whether the administration of oral PLE has an effect on the development of visible light induced pigmentation.

Conditions

  • Photodermatoses

Interventions

DRUG

Polypodium Leucotomos

\- PL 240mg to be taken by the patient for 28 days prior to irradiation with visible light

Sponsors & Collaborators

  • Henry Ford Health System

    lead OTHER

Principal Investigators

  • Iltefat H Hamzavi, MD · Henry Ford Hospital

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-07-01
Primary Completion
2017-02-14
Completion
2017-04-23

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02904798 on ClinicalTrials.gov